Sclerostin antibody treatment improves the bone phenotype of Crtap(−/−) mice, a model of recessive Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI) is characterized by low bone mass, poor bone quality and fractures. Standard treatment for OI patients is limited to bisphosphonates, which only incompletely correct the bone phenotype, and seem to be less effective in adults. Sclerostin neutralizing antibodies (Scl-Ab)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Bone Miner Res
Main Authors: Grafe, Ingo, Alexander, Stefanie, Yang, Tao, Lietman, Caressa, Homan, Erica P, Munivez, Elda, Chen, Yuqing, Jiang, Ming Ming, Bertin, Terry, Dawson, Brian, Asuncion, Franklin, Ke, Hua Zhu, Ominsky, Michael S, Lee, Brendan
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4862916/
https://ncbi.nlm.nih.gov/pubmed/26716893
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.2776
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados